My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 99

    1.

    Advances in the neuropharmacology of Parkinsonism.

    Calne DB, Kebabian J, Silbergeld E, Evarts E.

    Ann Intern Med. 1979 Feb;90(2):219-29. Review.PMID: 36020 [PubMed - indexed for MEDLINE]Related articles

    2.

    [Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease]

    Brücke T, Riederer P.

    Wien Med Wochenschr. 1986 Aug 31;136(15-16):401-8. German. PMID: 2878540 [PubMed - indexed for MEDLINE]Related articles

    3.

    Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease.

    Jiang C, Wan X, Jankovic J, Christian ST, Pristupa ZB, Niznik HB, Sundsmo JS, Le W.

    Clin Neuropharmacol. 2004 Mar-Apr;27(2):63-73.PMID: 15252266 [PubMed - indexed for MEDLINE]Related articles

    4.

    Developments in the pharmacology and therapeutics of parkinsonism.

    Calne DB.

    Ann Neurol. 1977 Feb;1(2):111-9. Review. No abstract available. PMID: 18978 [PubMed - indexed for MEDLINE]Related articles

    5.

    [Problems and future perspectives in the treatment of Parkinson's disease]

    Hens L, Hellemans J.

    Tijdschr Gerontol Geriatr. 1982 Aug;13(4):147-54. Dutch. PMID: 6127822 [PubMed - indexed for MEDLINE]Related articles

    6.

    The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.

    Chase TN.

    Drugs. 1998;55 Suppl 1:1-9. Review.PMID: 9483164 [PubMed - indexed for MEDLINE]Related articles

    7.

    Regional alpha-synuclein aggregation, dopaminergic dysregulation, and the development of drug-related visual hallucinations in Parkinson's disease.

    Papapetropoulos S.

    J Neuropsychiatry Clin Neurosci. 2006 Spring;18(2):149-57. Review.PMID: 16720791 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease.

    Thobois S, Guillouet S, Broussolle E.

    Neurophysiol Clin. 2001 Oct;31(5):321-40. Review.PMID: 11817273 [PubMed - indexed for MEDLINE]Related articles

    9.

    [The treatment of Parkinson's disease--adenosine A2A receptor antagonists]

    Matsubara E, Shoji M, Abe K.

    Nippon Rinsho. 2002 Jan;60(1):112-6. Review. Japanese. PMID: 11808320 [PubMed - indexed for MEDLINE]Related articles

    10.

    Peculiarities of L: -DOPA treatment of Parkinson's disease.

    Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R.

    Amino Acids. 2005 Mar;28(2):157-64. Epub 2005 Mar 9. Review.PMID: 15750845 [PubMed - indexed for MEDLINE]Related articles

    11.

    Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.

    Henchcliffe C, Schumacher HC, Burgut FT.

    Expert Rev Neurother. 2005 Nov;5(6):811-21. Review.PMID: 16274338 [PubMed - indexed for MEDLINE]Related articles

    12.

    GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease.

    Bartholini G, Scatton B, Zivkovic B, Lloyd KG.

    Adv Neurol. 1987;45:79-83.PMID: 3030072 [PubMed - indexed for MEDLINE]Related articles

    13.

    Parkinson's disease and its chemotherapy.

    Hornykiewicz O.

    Biochem Pharmacol. 1975 May 15;24(10):1061-5. No abstract available. PMID: 239718 [PubMed - indexed for MEDLINE]Related articles

    14.

    Prospects of glutamate antagonists in the therapy of Parkinson's disease.

    Blandini F, Greenamyre JT.

    Fundam Clin Pharmacol. 1998;12(1):4-12. Review.PMID: 9523179 [PubMed - indexed for MEDLINE]Related articles

    15.

    Pharmacotherapy of Parkinson's disease.

    Cohen MM, Scheife RT.

    Am J Hosp Pharm. 1977 May;34(5):531-8. Review.PMID: 326045 [PubMed - indexed for MEDLINE]Related articles

    16.

    Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.

    Oiwa Y, Yoshimura R, Nakai K, Itakura T.

    Brain Res. 2002 Aug 30;947(2):271-83.PMID: 12176170 [PubMed - indexed for MEDLINE]Related articles

    17.

    L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset.

    Svenningsson P, Gunne L, Andren PE.

    Neuroscience. 2000;99(3):457-68.PMID: 11029538 [PubMed - indexed for MEDLINE]Related articles

    18.

    Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease.

    Gerlach M, Double K, Reichmann H, Riederer P.

    J Neural Transm Suppl. 2003;(65):167-83. Review.PMID: 12946055 [PubMed - indexed for MEDLINE]Related articles

    19.

    Mechanism of action of dopaminergic agents in Parkinson's disease.

    Koller WC, Rueda MG.

    Neurology. 1998 Jun;50(6 Suppl 6):S11-4; discussion S44-8. Review.PMID: 9633680 [PubMed - indexed for MEDLINE]Related articles

    20.

    [Medicamentous strategy for improving the quality of life in the senescence]

    Knoll J.

    Wien Med Wochenschr Suppl. 1986;98:1-18. German. PMID: 3097965 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity